Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 15, Issue 5, 2004, Pages 325-329

  Nigro, G ^a   Sali, E ^a   Anceschi, M M ^a   Mazzocco, M ^a   Maranghi, L ^a   Clerico, A ^a   Castello, M A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Foscarnet; Liver fibrosis; Recurrent cytomegalovirus infection

Indexed keywords

FOSCARNET; GANCICLOVIR; VIRUS DNA;

ADULT; AMNION FLUID; ARTICLE; ASCITES; BASAL GANGLION; BRAIN REGION; CARCINOGENESIS; CASE REPORT; CATARACT; CLINICAL FEATURE; CONGENITAL DISORDER; CONGENITAL INFECTION; CULTURE MEDIUM; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; FEMALE; GESTATION PERIOD; HEPATOMEGALY; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; INFERTILITY; INTERSTITIAL PNEUMONIA; LABORATORY TEST; LIVER FIBROSIS; MALE; MICROPHTHALMIA; MUTAGENESIS; PRENATAL PERIOD; PRIORITY JOURNAL; RADIODIAGNOSIS; SIDE EFFECT; TREATMENT OUTCOME; URINALYSIS; VAGINAL DELIVERY;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DISEASE TRANSMISSION, VERTICAL; DNA, VIRAL; FEMALE; FOSCARNET; HUMANS; INFANT, NEWBORN; LIVER CIRRHOSIS; MALE; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ULTRASONOGRAPHY, PRENATAL;

EID: 3142772818     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/14767050410001701349     Document Type: Article

References (13)

1. Stagno S. Cytomegalovirus. In Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant, 5th edn. Philadelphia: WB Saunders, 2001:389-424
2. Fowler KB, Stagno S, Pass RF, et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326:663-7
3. Nigro G, Mazzocco M, Anceschi MM, et al. Prenatal diagnosis of fetal cytomegalovirus infection after primary or recurrent maternal infection. Obstet Gynecol 1999;94:909-14
4. Boppana SB, Fowler KB, Britt WJ, et al. Symptomatic congenital cytomegalovirus infection in infants born to mothers with pre-existing immunity to cytomegalovirus. Pediatrics 1999;104:55-60
5. Nigro G, Krzysztofiak A, Bartmann U, et al. Ganciclovir therapy for cytomegalovirus-associated liver disease in immunocompetent or immunocompromised children. Arch Virol 1997;142:573-80
6. Tajiri H, Kozaiwa K, Tanaka-Taya K, et al. Cytomegalovirus hepatitis confirmed by in situ hybridization in 3 immunocompetent infants. Scand J Infect Dis 2001;33:790-3
7. Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39:597-638
8. Nigro G, Bartmann U, Mattia S, et al. Acute hepatitis in childhood: virological, immunological and clinical aspects. Biomed Pharmacother 1992;46:155-60
9. Nigro G, La Torre R, Mazzocco M, et al. Multi-system cytomegalovirus fetopathy by recurrent infection in a pregnant woman with hepatitis B. Prenat Diagn 1999;19:1070-2
10. Zaia JA. Pathogenesis of CMV-associated disease in 1990. Transplant 1991;23 (Suppl 3):1-4
11. Chrisp P, Clissold SP. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991;41:104-29
12. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000;96:3286-9
13. Ohta H, Matsuda Y, Tokimara S, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA. Bone Marrow Transplant 2001;27:1141-5